Study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer
10.3760/cma.j.issn.1006-9801.2010.01.009
- VernacularTitle:一线序贯应用厄洛替尼与化疗治疗晚期非小细胞肺癌的临床研究
- Author:
Zhiwei CHEN
;
Zhengbo SONG
;
Yongfeng YU
;
Ziming LI
;
Shun LU
;
Meilin LIAO
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Antineoplastic combined chemotherapy protocols;
Erlotinib;
Sequential therapy
- From:
Cancer Research and Clinic
2010;22(1):32-34
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the short-term efficacy and safety of sequential administration of erlotinib and chemotherapy in unselected, chemonaive patients with advanced non-small-cell lung cancer (NSCLC). Methods Previously-untreated patients (n=23) with stage Ⅲ_B/Ⅳ NSCLC and ECOG PS of 0/1 received erlotinib (150 mg/d) on days 15-28 of a 4-week cycle that included gemcitabine (1250 mg/m~2, days 1 and 8), and either cisplatin (75 mg/m~2, day 1) or carboplatin (AUC=5, day 1). The primary end points were tumor response rate and safety. Results 23 patients received a total of 95 cycles of treatment, and all were evaluable for efficacy and toxicity. The overall response rate was 30.4%, 0 case achieved complete responses (CR), 7 cases (30.4%) achieved partial responses (PR), 14 cases (60.9 %) achieved stable disease (SD), 2 cases (8.7 %) achieved progression disease (PD). The disease control rate was 91.3 %. The sequential administration of erlotinib following gemcitabine/platinum chemotherapy was well tolerated. The major grade 3 treatment-related adverse events were eutropenia (13.4%), rash (8.7%), nausea (8.7%) and thrombocytopenia (8.7%). No treatment-related interstitial lung disease. Conclusion equential administration of erlotinib following gemcitabine/platinum chemotherapy was effective, and the toxicity was tolerable. This treatment strategy warrants further investigation.